SCHEMBL5547664

SCHEMBL5547664

CC1Cc2ccc(O)cc2O1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.55
CREBBP Q92793 1/20 0.55
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ESR1 P03372 2/20 0.47
ESR2 Q92731 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
TTR P02766 1/20 0.47
CHRNA7 P36544 2/20 0.43
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541364 0.85 TDP1 (0.60) BRD4CREBBPALDH1A1CYP3A4MAPT
SCHEMBL9749055 0.81 ESR1 (0.61) ESR1ESR2CHRNA7
SCHEMBL9749565 0.81 KDM4E (0.47) BRD4CREBBPALDH1A1KDM4ECYP3A4
SCHEMBL7916564 0.78 CREBBP (0.50) BRD4CREBBPALDH1A1KDM4ETDP1
SCHEMBL21657656 0.78 CREBBP (0.50) BRD4CREBBPALDH1A1KDM4ETDP1
SCHEMBL13799419 0.77 AKR1B1 (0.44) BRD4CREBBPALDH1A1KDM4ETDP1
SCHEMBL16372547 0.77 TDP1 (0.44) BRD4CREBBPALDH1A1KDM4EMAPT
SCHEMBL18536396 0.77 AKR1B1 (0.44) ALDH1A1KDM4ETDP1MAOBGAA
SCHEMBL5547658 0.77 ALDH1A1 (0.47) BRD4CREBBPALDH1A1KDM4EMAPT
SCHEMBL18114486 0.77 PBRM1 (0.56) ALDH1A1KDM4EMAPTTDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7923457-B2 Quinoline derivatives AGOURON PHARMACEUTICALS INC. (US) 2011-04-12 US disclosed
US-20090069316-A1 NOVEL QUINOLINE DERIVATIVES AGOURON PHARMACEUTICALS, INC. 2009-03-12 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-7157470-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
EP-0333498-B1 Process for preparation of a gelled polyester for toner MITSUBISHI RAYON CO (JP) 1997-07-16 EP disclosed
US-5368968-A Modified polyester resins, a process for their preparation and toners containing such polyester resins BAYER AKTIENGESELLSCHAFT (DE) 1994-11-29 US disclosed
US-4980448-A OFFSET AND BLOCKING RESISTANCE; SELF-CHARGING; SHARP COPIED IMAGES MITSUBISHI RAYON COMPANY, LTD. (JP) 1990-12-25 US disclosed
EP-0333498-A2 Process for preparation of a gelled polyester for toner MITSUBISHI RAYON CO., LTD. (JP) 1989-09-20 EP disclosed
US-4002647-A INSECTICIDES HOFFMANN-LA ROCHE INC. (US) 1977-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069316-A1 NOVEL QUINOLINE DERIVATIVES COQ8B, COQ8A, MCM5 BRD4 180/4885CREBBP 1323/4885ALDH1A1 2332/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 BRD4 1012/4885CREBBP 1702/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.